Patents

Iomai Corp. awarded key vaccine technology patent for its transcutaneous immunization technology

Published in Medical Letter on the CDC and FDA, July 16th, 2006

Iomai Corp. (IOMI) announced that the U.S. Patent & Trademark Office has awarded a new U.S. patent "Adjuvant for transcutaneous immunization" (number 7,037,499) which outlines methods for inducing an immune response to Iomai's skin-patch-based vaccines.

The patent's claims expand the coverage for the company's transcutaneous immunization (TCI) technology, according to the company a unique method of vaccine delivery with benefits including needle-free administration and the ability to deliver types of vaccines that are not viable by an intramuscular route. Iomai's TCI technology uses a patch applied to the skin like a bandage and worn for several hours to deliver vaccine...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2006-07-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry